|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||188.37 - 196.01|
|52 Week Range||162.29 - 327.32|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||89.70|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||312.56|
Subscribe to Yahoo Finance Plus to view Fair Value for RGENLearn more
Repligen (NASDAQ: RGEN) and ResMed (NYSE: RMD) are two stocks which could fit that bill with their proven track records and growing opportunities. Repligen offers a unique way to invest in the healthcare space. Operating in both the downstream and upstream processes of drug development, Repligen sells products in the areas of filtration, chromatography, process analytics, and proteins.
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.
Investment company Accel Wealth Management (Current Portfolio) buys Vanguard Total Stock Market ETF, iShares Core Dividend Growth ETF, FIRST TR EXCHANGE, Vanguard Growth ETF, Recon Capital NASDAQ-100 Covered Call ETF, sells First Trust NASDAQ Clean Edge Green Energy Idx Fd, , Meta Platforms Inc, Vanguard Mortgage-Backed Securities ETF, BTC iShares U.S.